| 1. | | Recruiting | Adjunct CellCept (mycophenolate mofetil) with Reduced Corticosteroids in Subjects with Myasthenia Gravis
Condition: Myasthenia Gravis |
| 2. | | Recruiting | Anastrozole With or Without Trastuzumab in Treating Postmenopausal Women With Metastatic Breast Cancer
Conditions: stage IV breast cancer; recurrent breast cancer |
| 3. | | Recruiting | Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Conditions: Colon Cancer; Rectal Cancer |
| 4. | | Recruiting | Capecitabine in Combo with XELOX vs. Fluorouracil/Leucovorin with Oxaliplatin (FOLFOX4) as Treatment for Patients with Metastatic Colorectal Cancer
Conditions: Colorectal Cancer; Metastases |
| 5. | | Recruiting | Double-blind, partially randomized, parallel group, multicenter study to assess the efficacy and safety of 100 mg and 150 mg monthly oral ibandronate in women with postmenopausal osteoporosis having completed the phase III oral ibandronate trial
Condition: Osteoporosis |
| 6. | | Recruiting | Effectiveness of KOS-862 in the Treatment of Lung Cancer
Condition: Lung Cancer |
| 7. | | Recruiting | Efficacy and safety of Pegasys plus Copegus in patients with chronic Hepatitis C who are unable to tolerate or who do not respond to 12 weeks of therapy with PEG-Intron plus Rebetol/Ribavirin.
Condition: Hepatitis C |
| 8. | | Recruiting | Evaluation of Differing Taxanes/Taxane Combinations on the Outcomes of Patients with Operable Breast Cancer
Condition: Breast Cancer |
| 9. | | Recruiting | Evaluation of the efficacy and safety of a high induction dose of Pegasys in combination with Copegus in patients with Chronic Hepatitis C who did not respond to previous treatment with PEG-Intron in combination with Rebetol/Ribavirin.
Condition: Hepatitis |
| 10. | | Recruiting | Evaluation of the viral kinetics and pharmacokinetics of Pegasys plus Copegus and PEG-Intron plus Rebetol in patients with Chronic Hepatitis C and previously untreated with an interferon.
Condition: Hepatitis C |
| 11. | | Recruiting | An Open Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose vs Concentration Controlled CellCept Regimens for Patients Following a Single Organ Renal Transplantation in Combination with Full Dose and Reduced Dose Calcineurin Inhibitors
Condition: renal transplant |
| 12. | | Recruiting | An Open-Label Randomized Phase II Study of Two Different Dosing Regimens of Capecitabine in Combo with Intravenous Docetaxel (Q3W) in Patients with Locally Advanced and/or Metastatic Breast Cancer
Condition: Breast (combo) and Colon Cancer (monotherapy) |
| 13. | | Not yet recruiting | An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia.
Condition: Renal Anemia |
| 14. | | Not yet recruiting | An Open-Label, Randomized Phase III Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer.
Condition: Breast Cancer |
| 15. | | Recruiting | An open-label, randomized, multi-center, parallel group study to demonstrate correction of anemia using intravenous injections of RO0503821 in patients with chronic kidney disease who are on dialysis
Condition: Renal Anemia |
| 16. | | Recruiting | Pegasys in Combination with Copegus in Previously Untreated Patients with Chronic Hepatitis C Genotype 1
Condition: Chronic Hepatitis C |
| 17. | | Recruiting | Pegasys in Combination with Copegus in Previously Untreated Patients with Chronic Hepatitis C virus Genotype 2 or 3
Condition: Chronic Hepatitis C |
| 18. | | Recruiting | A phase II open-label, randomized, active-controlled study comparing the efficacy and safety of once daily Fuzeon (enfuvirtide) dosing versus the currently recommended twice daily dosing in HIV-1 infected treatment experienced patients.
Condition: HIV Disease |
| 19. | | Recruiting | A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered intravenously for the maintenance treatment of anemia in patients w/ chronic kidney disease who are on dialysis
Condition: Renal Anemia |
| 20. | | Recruiting | A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered intravenously for the maintenance treatment of anemia in patients w/ chronic kidney disease who are on dialysis.
Condition: Renal Anemia |
| 21. | | Recruiting | A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered subcutaneously for the maintenance treatment of anemia in patients w/ chronic kidney disease who are on dialysis
Condition: Renal Anemia |
| 22. | | Recruiting | Randomized, controlled, open-label, multicenter, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered w/ pre-filled syringes for the maintenance treatment of anemia in pts w/ chronic kidney disease who are on dialysis
Condition: Renal Anemia |
| 23. | | Not yet recruiting | A Randomized, Open-Label, Multicenter, Phase III Trial Comparing Regimens of Adriamycin plus Cytoxan Followed by Either Taxotere or Taxotere plus Xeloda as Adjuvant Therapy for Female Patients with High-Risk Breast Cancer
Condition: Adjuvant Breast Cancer |
| 24. | | Recruiting | Rituximab/Fludarabine/Cyclophosphamide (FCR) versus Fludarabine/Cyclophosphamide (FC) Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia |
| 25. | | Recruiting | RO0503821 Treatment for Correction of Anemia in Chronic Kidney Disease Patients
Conditions: Anemia; Kidney Disease |
| 26. | | Not yet recruiting | A Safety and Efficacy Study of Prophylactically Administered Pegylated Interferon alfa-2a (Pegasys) plus Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C
Condition: Hepatitis C |
| 27. | | Recruiting | Safety and Pharmacokinetics of Valganciclovir syrup formulation in pediatric solid organ transplant recipients
Condition: Prevention of CMV Disease in Solid Organ Transplant |
| 28. | | Recruiting | Safety, feasibility and tolerability of Pegasys plus Copegus in previous intravenous drug users (IVDUs) who are infected with Chronic Hepatitis C and are currently enrolled in a methadone maintenance treatment program
Condition: Hepatitis C |
| 29. | | Recruiting | Study of Capecitabine in Combo with Oxaliplatin (XELOX), Bevacizumab, and Fluorouracil/Leucovorin with Oxaliplatin (FOLFOX-4) as First-line Treatments for Patients with Metastatic Colorectal Cancer
Conditions: Colorectal Cancer; Metastases |
